Influence of combined angiotensin-converting enzyme inhibitors and spironolactone on serum K+, Mg2+, and Na+ concentrations in small dogs with degenerative mitral valve disease

Journal of Veterinary Cardiology

Volumn 9, Issue 2, 2007, Pages 103-108

  Thomason, Justin D ^a   Rockwell, Jennifer E ^a   Fallaw, Tiffany K ^a   Calvert, Clay A ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

ACE inhibitors; Mitral regurgitation; Spironolactone

Indexed keywords

BENAZEPRIL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRIL MALEATE; MAGNESIUM ION; NITROGEN; POTASSIUM ION; SODIUM ION; SPIRONOLACTONE; UREA;

ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEGENERATIVE DISEASE; DOG; DOG DISEASE; DRUG DOSE INCREASE; DRUG SAFETY; FEMALE; FOLLOW UP; HEART ATRIUM ENLARGEMENT; HYPERKALEMIA; HYPONATREMIA; MAGNESIUM BLOOD LEVEL; MALE; MITRAL VALVE DISEASE; NONHUMAN; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SODIUM BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DIURETICS; DOG DISEASES; DOGS; DRUG INTERACTIONS; FEMALE; HYPERKALEMIA; HYPONATREMIA; MAGNESIUM; MALE; MITRAL VALVE INSUFFICIENCY; POTASSIUM; RETROSPECTIVE STUDIES; SAFETY; SODIUM; SPIRONOLACTONE;

ANIMALIA; CANIS FAMILIARIS;

EID: 36749055188     PISSN: 17602734     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvc.2007.08.002     Document Type: Article

References (28)

1. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316 (1987) 1429-1434
2. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327 (1992) 685-691
3. The COVE Study Group. Controlled clinical evaluation of enalapril in dogs with heart failure: results of the Cooperative Veterinary Enalapril Study Group. J Vet Intern Med 9 (1995) 243-252
4. The IMPROVE Study Group. Acute and short-term hemodynamic, echocardiographic, and clinical effects of enalapril maleate in dogs with naturally acquired heart failure: results of the Invasive Multicenter Prospective Veterinary Evaluation of Enalapril Study. J Vet Intern Med 9 (1995) 234-240
5. Ettinger S.J., Benitz A.M., Ericsson G.F., Cifelli S., Jernigan A.D., Longhofer S.L., Trimboli W., and Hanson P.D. Effects of enalapril maleate on survival of dogs with naturally acquired heart failure. The Long-Term Investigation of Veterinary Enalapril (LIVE) Study Group. J Am Vet Med Assoc 213 (1998) 1573-1577
6. Kitagawa H., Wakamiya H., Kitoh K., Kuwahara Y., Ohba Y., Isaji M., Iwasaki T., Nakano M., and Sasaki Y. Efficacy of monotherapy with benazepril, an angiotensin converting enzyme inhibitor, in dogs with naturally acquired chronic mitral insufficiency. J Vet Med Sci 59 (1997) 513-520
7. The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 78 (1996) 902-907
8. Dahlström U., and Karlsson E. Captopril and spironolactone therapy for refractory congestive heart failure. Am J Cardiol 71 (1993) 29A-33A
9. Schepkens H., Vanholder R., Billouw J.M., and Lameire N. Life threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 110 (2001) 438-441
10. Berry C., and McMurray J. Life threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone. Am J Med 111 (2001) 587-594
11. Barr C.S., Lang C.C., Hanson J., Arnott M., Kennedy N., and Struthers A.D. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 76 (1995) 1259-1265
12. Greenblatt D.J., and Koch-Weser J. Adverse reactions to spironolactone - a report from the Boston Collaborative Drug Surveillance Program. J Am Vet Med Assoc 225 (1973) 40-43
13. Papich M.J. Incompatible critical care drug combinations. In: Kirk R.W., and Bonagura J.D. (Eds). Current veterinary therapy XII (1995), WB Saunders, Philadelphia 194-199
14. Kvart C., and Häggström J. Acquired valvular heart disease. In: Ettinger S.J., and Feldman E.C. (Eds). Textbook of veterinary internal medicine. 5th ed. (2000), WB Saunders, Philadelphia 787-800
15. Opie L.H., Poole-Wilson P.A., Sonnenblick E., and Chatterjee K. Angiotensin-converting enzyme inhibitors. Contrast with conventional vasodilators. In: Opie L.H. (Ed). Drugs for the heart. 4th ed. (1995), WB Saunders, Philadelphia 105-144
16. Farquharson C.A.J., and Struthers A.D. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/ angiotensin II conversion in patients with chronic heart failure. Circulation 101 (2000) 594-597
17. Sisson D., and Kittleson M.D. Management of heart failure: principles of treatment, therapeutic strategies, and pharmacology. In: Fox P.R., Sisson D., and Moise N.S. (Eds). Textbook of canine and feline cardiology. 2nd ed. (1999), WB Saunders, Philadelphia 216-250
18. Bond B.R. Myocardial diseases. In: Leib M.S., and Monroe W.E. (Eds). Practical small animal internal medicine (1997), WB Saunders, Philadelphia 201-234
19. O'Grady M.R., Bonagura J.D., Powers S.D., and Herring D.S. Quantitative cross-sectional echocardiography in the normal dog. Vet Radiol 27 (1986) 34-39
20. Zannad F. Angiotensin-converting enzyme inhibitor and spironolactone combination therapy - new objectives in congestive heart failure treatment. Am J Cardiol 71 (1993) 34A-39A
21. Weber K.T. Aldosterone and spironolactone in heart failure. N Engl J Med 341 (1999) 753-755
22. Rodgers J.E., and Patterson J.H. The role of the renin-angiotensin-aldosterone system in the management of heart failure. Pharmacotherapy 20 (2000) 368S-378S
23. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., Palensky J., and Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 (1999) 709-717
24. Struthers A.D. Aldosterone escape during ACE inhibitor therapy in chronic heart failure. Eur Heart J 16 Suppl. N (1995) 103-106
25. Amberger C., Chetboul V., Bomassi E., Rougier S., Woehrlé F., and Thoulon F. Comparison of the effects of imidapril and enalapril in a prospective, multicentric randomized trial in dogs with naturally acquired heart failure. J Vet Cardiol 6 (2004) 9-16
26. The BENCH (BENazepril in Canine Heart disease) Study Group. The effect of benazepril on survival times and clinical signs of dogs with congestive heart failure: results of a multicenter, prospective, randomized, double-blinded, placebo-controlled, long-term clinical trial. J Vet Cardiol 1 (1999) 7-18
27. Linen P., and Petrov V. Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol 32 (2000) 865-879
28. Craig A.J., Seguela J., Queau Y., Murgier P., Concordet D., Fleeman L.M., Mimouni P., Braun J.P., Germain C., and Lefebvre H.P. Redefining the reference interval for plasma creatinine in dogs: effect of age, gender, body weight, and breed [abstract]. J Vet Intern Med 20 (2006) 766-767